All In Biotech

Free tool

FAERS Monitor: Conjupri

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212895 or its brand name (Conjupri, Levamlodipine Maleate). Reports on generic versions are filed under their own applications.

Reports

125

Serious

119

95% of reports

Hospitalization

74

Death reported

14

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea12
  • fatigue8
  • hypertension8
  • nausea8
  • pain8
  • arthralgia7
  • drug ineffective7
  • hypoaesthesia7
  • malaise7
  • pneumonia7
  • constipation6
  • decreased appetite6
  • dyspnoea6
  • off label use6
  • pain in extremity6

Reports by year received

View as table
YearReports
20122
20135
201410
20151
201610
201710
201820
201911
20209
202110
20228
20239
20245
20259
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,034 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypoaesthesiaSignal77.93.836
hypertensionSignal86.43.331
constipationSignal64.62.114
decreased appetiteSignal64.32.012
pneumoniaSignal73.61.811
pain in extremitySignal63.41.68
diarrhoeaSignal123.11.816
arthralgiaSignal72.81.47
malaiseSignal72.71.36
painSignal82.21.14
dyspnoea61.80.81
fatigue81.70.92
nausea81.70.92
off label use61.20.50
drug ineffective70.90.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.